# cfr-section 21 CFR 312.84

IRI: <https://ontology.bommaritollc.com/id/01a0f094-c4ae-77a9-9fac-9f0fdd50e2fe>

Type: [adms:Identifier](http://www.w3.org/ns/adms#Identifier)

- `dcterms:conformsTo`: [cfr-section](https://ontology.bommaritollc.com/vocab/scheme/cfr-section)
- `prov:wasDerivedFrom`: [evidence from https://www.govinfo.gov/app/details/CFR-2025-title21-vol1](https://ontology.bommaritollc.com/id/01a0f094-c4ad-70e9-8fec-e2b0afe143f9)
- `skos:notation`: 21 CFR 312.84

## Elsewhere

- [Source](https://www.govinfo.gov/app/details/CFR-2025-title21-vol1) (www.govinfo.gov)

## Pointing here

- Its identifier, from (1; `adms:identifier`):
  - [21 CFR 312.84 Risk-benefit analysis in review of marketing applications for drugs to treat life-threatening and severely-debilitating illnesses.](https://ontology.bommaritollc.com/id/01a0f094-c4ad-70e9-8fec-e2b1899763eb)

---
Also as: [Turtle](https://ontology.bommaritollc.com/id/01a0f094-c4ae-77a9-9fac-9f0fdd50e2fe.ttl), [JSON-LD](https://ontology.bommaritollc.com/id/01a0f094-c4ae-77a9-9fac-9f0fdd50e2fe.jsonld), [N-Triples](https://ontology.bommaritollc.com/id/01a0f094-c4ae-77a9-9fac-9f0fdd50e2fe.nt), [HTML](https://ontology.bommaritollc.com/id/01a0f094-c4ae-77a9-9fac-9f0fdd50e2fe)
Cite as: cfr-section 21 CFR 312.84. bc-ontology, release 0.1.0-rc38, 2026-10-21. https://ontology.bommaritollc.com/id/01a0f094-c4ae-77a9-9fac-9f0fdd50e2fe
Release 0.1.0-rc38, graph hash 05350a11cf9d0c42fba51e92b877115781ab65cb92afcd6b172ff9f8f4abf0bd.
